001     281877
005     20251110094613.0
024 7 _ |a 10.1093/brain/awaf195
|2 doi
024 7 _ |a pmid:40424598
|2 pmid
024 7 _ |a 0006-8950
|2 ISSN
024 7 _ |a 1460-2156
|2 ISSN
037 _ _ |a DZNE-2025-01248
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Planche, Vincent
|0 0000-0003-3713-227X
|b 0
245 _ _ |a Anatomical progression of genetic frontotemporal lobar degeneration across the lifespan.
260 _ _ |a Oxford
|c 2025
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1762764195_27492
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The recent development of brain charts for the human lifespan offers an ideal modelling framework for pathologies such as genetic frontotemporal lobar degeneration (FTLD) which likely involve both neurodevelopmental and neurodegenerative processes over a lifetime. We have therefore combined this new methodological approach with MRI data from asymptomatic and symptomatic subjects, carrying C9orf72, MAPT or GRN mutations from the Genetic FTD Initiative (GENFI) and the ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) study. We analysed 37 532 MRIs from control subjects covering the entire lifespan and a total of 1341 MRIs from subjects with a pathogenic FTLD mutation, aged from 18 to 86 years old. We detected the first significant regional brain volume differences on average at 27 years old in C9orf72 and MAPT mutation carriers, and at 42 years old in GRN mutation carriers. The delay between the onset of anatomical changes and the average age of symptom onset (i.e. the presymptomatic phase) was 13 years for MAPT, 17 years for GRN and 34 years for C9orf72 mutation carriers. In terms of effect size, cumulative atrophy over the lifespan was twice as severe in affected brain regions in MAPT than in GRN or C9orf72 mutation carriers. However, the neurodegenerative process was spatially more extensive in C9orf72 (35 brain regions affected out of the 61 tested) compared with GRN or MAPT mutation carriers (25 and 18 regions, respectively). Schematically, the chronological staging of atrophy progression showed an initial involvement of the thalamus in C9orf72 expansion carriers, followed by the fronto-temporo-insular regions, the striatum and the amygdala. In GRN mutation carriers, atrophy began in fronto-insular areas, before progressing toward subcortical structures. In MAPT mutation carriers, atrophy affected the anterior temporal pole with the amygdala and hippocampus, before progressing to fronto-insular regions and the striatum. Our results using brain charts for the human lifespan show that C9orf72 is the most diffuse but also the slowest to emerge among genetic FTLD. MAPT FTLD is more aggressive and focal, while GRN FTLD is also rapidly progressive but with a later onset of the presymptomatic phase. Beyond quantification of the anatomical progression of genetic FTLD over the lifespan, these results may help determine the best timing to model and test disease-modifying strategies in FTLD, and monitor their effect in future clinical trials.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a C9orf72
|2 Other
650 _ 7 |a GRN
|2 Other
650 _ 7 |a MAPT
|2 Other
650 _ 7 |a brain charts
|2 Other
650 _ 7 |a frontotemporal lobar degeneration
|2 Other
650 _ 7 |a lifespan
|2 Other
650 _ 7 |a Progranulins
|2 NLM Chemicals
650 _ 7 |a C9orf72 Protein
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a C9orf72 protein, human
|2 NLM Chemicals
650 _ 7 |a GRN protein, human
|2 NLM Chemicals
650 _ 7 |a MAPT protein, human
|2 NLM Chemicals
650 _ 7 |a Intercellular Signaling Peptides and Proteins
|2 NLM Chemicals
650 _ 7 |a Proteins
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Frontotemporal Lobar Degeneration: genetics
|2 MeSH
650 _ 2 |a Frontotemporal Lobar Degeneration: pathology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Progranulins
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a C9orf72 Protein: genetics
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a tau Proteins: genetics
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Adolescent
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
650 _ 2 |a Mutation: genetics
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Atrophy: pathology
|2 MeSH
650 _ 2 |a Longitudinal Studies
|2 MeSH
650 _ 2 |a Intercellular Signaling Peptides and Proteins: genetics
|2 MeSH
650 _ 2 |a Proteins: genetics
|2 MeSH
700 1 _ |a Mansencal, Boris
|0 0000-0002-9190-4819
|b 1
700 1 _ |a Fonov, Vladimir
|b 2
700 1 _ |a Manjon, José V
|b 3
700 1 _ |a Tourdias, Thomas
|0 0000-0002-7151-6325
|b 4
700 1 _ |a Bouzigues, Arabella
|b 5
700 1 _ |a Russell, Lucy L
|b 6
700 1 _ |a Foster, Phoebe H
|b 7
700 1 _ |a Ferry-Bolder, Eve
|b 8
700 1 _ |a van Swieten, John C
|b 9
700 1 _ |a Jiskoot, Lize C
|0 0000-0002-1120-1858
|b 10
700 1 _ |a Seelaar, Harro
|0 0000-0003-1989-7527
|b 11
700 1 _ |a Sanchez-Valle, Raquel
|0 0000-0001-7750-896X
|b 12
700 1 _ |a Laforce, Robert
|b 13
700 1 _ |a Graff, Caroline
|0 0000-0002-9949-2951
|b 14
700 1 _ |a Galimberti, Daniela
|b 15
700 1 _ |a Vandenberghe, Rik
|0 0000-0001-6237-2502
|b 16
700 1 _ |a de Mendonça, Alexandre
|b 17
700 1 _ |a Tiraboschi, Pietro
|b 18
700 1 _ |a Santana, Isabel
|b 19
700 1 _ |a Gerhard, Alexander
|0 0000-0002-8071-6062
|b 20
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 21
700 1 _ |a Sorbi, Sandro
|b 22
700 1 _ |a Otto, Markus
|b 23
700 1 _ |a Bertoux, Maxime
|0 0000-0002-5283-503X
|b 24
700 1 _ |a Lebouvier, Thibaud
|b 25
700 1 _ |a Butler, Chris R
|b 26
700 1 _ |a Le Ber, Isabelle
|b 27
700 1 _ |a Finger, Elizabeth
|b 28
700 1 _ |a Tartaglia, Maria Carmela
|b 29
700 1 _ |a Masellis, Mario
|b 30
700 1 _ |a Rowe, James B
|b 31
700 1 _ |a Synofzik, Matthis
|0 P:(DE-2719)2811275
|b 32
|u dzne
700 1 _ |a Moreno, Fermin
|b 33
700 1 _ |a Borroni, Barbara
|b 34
700 1 _ |a Rohrer, Jonathan D
|b 35
700 1 _ |a Collins, D Louis
|0 0000-0002-8432-7021
|b 36
700 1 _ |a Ducharme, Simon
|0 0000-0002-7309-1113
|b 37
700 1 _ |a Coupé, Pierrick
|b 38
700 1 _ |a Consortium, ALLFTD
|b 39
700 1 _ |a Initiative, the Genetic FTD
|b 40
|e Collaboration Author
700 1 _ |a Convery, Rhian
|b 41
|e Contributor
700 1 _ |a Bocchetta, Martina
|b 42
|e Contributor
700 1 _ |a Cash, David
|b 43
|e Contributor
700 1 _ |a Goldsmith, Sophie
|b 44
|e Contributor
700 1 _ |a Samra, Kiran
|b 45
|e Contributor
700 1 _ |a Thomas, David L
|b 46
|e Contributor
700 1 _ |a Malpetti, Maura
|b 47
|e Contributor
700 1 _ |a Alberici, Antonella
|b 48
|e Contributor
700 1 _ |a Premi, Enrico
|b 49
|e Contributor
700 1 _ |a Gasparotti, Roberto
|b 50
|e Contributor
700 1 _ |a Cantoni, Valentina
|b 51
|e Contributor
700 1 _ |a Arighi, Andrea
|b 52
|e Contributor
700 1 _ |a Fenoglio, Chiara
|b 53
|e Contributor
700 1 _ |a Borracci, Vittoria
|b 54
|e Contributor
700 1 _ |a Serpente, Maria
|b 55
|e Contributor
700 1 _ |a Carandini, Tiziana
|b 56
|e Contributor
700 1 _ |a Rotondo, Emanuela
|b 57
|e Contributor
700 1 _ |a Rossi, Giacomina
|b 58
|e Contributor
700 1 _ |a Giaccone, Giorgio
|b 59
|e Contributor
700 1 _ |a Di Fede, Giuseppe
|b 60
|e Contributor
700 1 _ |a Caroppo, Paola
|b 61
|e Contributor
700 1 _ |a Prioni, Sara
|b 62
|e Contributor
700 1 _ |a Redaelli, Veronica
|b 63
|e Contributor
700 1 _ |a Tang-Wai, David
|b 64
|e Contributor
700 1 _ |a Rogaeva, Ekaterina
|b 65
|e Contributor
700 1 _ |a Krüger, Johanna
|b 66
|e Contributor
700 1 _ |a Castelo-Branco, Miguel
|b 67
|e Contributor
700 1 _ |a Freedman, Morris
|b 68
|e Contributor
700 1 _ |a Keren, Ron
|b 69
|e Contributor
700 1 _ |a Black, Sandra
|b 70
|e Contributor
700 1 _ |a Mitchell, Sara
|b 71
|e Contributor
700 1 _ |a Shoesmith, Christen
|b 72
|e Contributor
700 1 _ |a Bartha, Robart
|b 73
|e Contributor
700 1 _ |a Rademakers, Rosa
|b 74
|e Contributor
700 1 _ |a Poos, Jackie
|b 75
|e Contributor
700 1 _ |a Papma, Janne M
|b 76
|e Contributor
700 1 _ |a Giannini, Lucia
|b 77
|e Contributor
700 1 _ |a de Boer, Liset
|b 78
|e Contributor
700 1 _ |a de Houwer, Julie
|b 79
|e Contributor
700 1 _ |a van Minkelen, Rick
|b 80
|e Contributor
700 1 _ |a Pijnenburg, Yolande
|b 81
|e Contributor
700 1 _ |a Nacmias, Benedetta
|b 82
|e Contributor
700 1 _ |a Ferrari, Camilla
|b 83
|e Contributor
700 1 _ |a Polito, Cristina
|b 84
|e Contributor
700 1 _ |a Lombardi, Gemma
|b 85
|e Contributor
700 1 _ |a Bessi, Valentina
|b 86
|e Contributor
700 1 _ |a Fainardi, Enrico
|b 87
|e Contributor
700 1 _ |a Chiti, Stefano
|b 88
|e Contributor
700 1 _ |a Nilsson, Mattias
|b 89
|e Contributor
700 1 _ |a Viklund, Henrik
|b 90
|e Contributor
700 1 _ |a Rydell, Melissa Taheri
|b 91
|e Contributor
700 1 _ |a Jelic, Vesna
|b 92
|e Contributor
700 1 _ |a Öijerstedt, Linn
|b 93
|e Contributor
700 1 _ |a Langheinrich, Tobias
|b 94
|e Contributor
700 1 _ |a Lladó, Albert
|b 95
|e Contributor
700 1 _ |a Antonell, Anna
|b 96
|e Contributor
700 1 _ |a Olives, Jaume
|b 97
|e Contributor
700 1 _ |a Balasa, Mircea
|b 98
|e Contributor
700 1 _ |a Borrego-Ecija, Sergi
|b 99
|e Contributor
700 1 _ |a Verdelho, Ana
|b 100
|e Contributor
700 1 _ |a Maruta, Carolina
|b 101
|e Contributor
700 1 _ |a Costa-Coelho, Tiago
|b 102
|e Contributor
700 1 _ |a Miltenberger, Gabriel
|b 103
|e Contributor
700 1 _ |a do Couto, Frederico Simões
|b 104
|e Contributor
700 1 _ |a Gabilondo, Alazne
|b 105
|e Contributor
700 1 _ |a Croitoru, Ioana
|b 106
|e Contributor
700 1 _ |a Tainta, Mikel
|b 107
|e Contributor
700 1 _ |a Barandiaran, Myriam
|b 108
|e Contributor
700 1 _ |a Alves, Patricia
|b 109
|e Contributor
700 1 _ |a Bender, Benjamin
|b 110
|e Contributor
700 1 _ |a Mengel, David
|0 P:(DE-2719)9000375
|b 111
|e Contributor
|u dzne
700 1 _ |a Graf, Lisa
|0 P:(DE-2719)9001369
|b 112
|e Contributor
|u dzne
700 1 _ |a Vogels, Annick
|b 113
|e Contributor
700 1 _ |a Vandenbulcke, Mathieu
|b 114
|e Contributor
700 1 _ |a Van Damme, Philip
|b 115
|e Contributor
700 1 _ |a Bruffaerts, Rose
|b 116
|e Contributor
700 1 _ |a Poesen, Koen
|b 117
|e Contributor
700 1 _ |a Rosa-Neto, Pedro
|b 118
|e Contributor
700 1 _ |a Montembeault, Maxime
|b 119
|e Contributor
700 1 _ |a Migliaccio, Raphaella Lara
|b 120
|e Contributor
700 1 _ |a Burgos, Ninon
|b 121
|e Contributor
700 1 _ |a Rinaldi, Daisy
|b 122
|e Contributor
700 1 _ |a Prix, Catharina
|0 P:(DE-2719)9001508
|b 123
|e Contributor
|u dzne
700 1 _ |a Wlasich, Elisabeth
|b 124
|e Contributor
700 1 _ |a Wagemann, Olivia
|0 P:(DE-2719)9001249
|b 125
|e Contributor
|u dzne
700 1 _ |a Schönecker, Sonja
|b 126
|e Contributor
700 1 _ |a Bernhardt, Alexander Maximilian
|0 P:(DE-2719)9002620
|b 127
|e Contributor
|u dzne
700 1 _ |a Stockbauer, Anna
|0 P:(DE-2719)9002610
|b 128
|e Contributor
|u dzne
700 1 _ |a Lombardi, Jolina
|b 129
|e Contributor
700 1 _ |a Anderl-Straub, Sarah
|b 130
|e Contributor
700 1 _ |a Rollin, Adeline
|b 131
|e Contributor
700 1 _ |a Kuchcinski, Gregory
|b 132
|e Contributor
700 1 _ |a Deramecourt, Vincent
|b 133
|e Contributor
700 1 _ |a Durães, João
|b 134
|e Contributor
700 1 _ |a Lima, Marisa
|b 135
|e Contributor
700 1 _ |a Leitão, Maria João
|b 136
|e Contributor
700 1 _ |a Almeida, Maria Rosario
|b 137
|e Contributor
700 1 _ |a Tábuas-Pereira, Miguel
|b 138
|e Contributor
700 1 _ |a Afonso, Sónia
|b 139
|e Contributor
700 1 _ |a Lemos, João
|b 140
|e Contributor
773 _ _ |a 10.1093/brain/awaf195
|g Vol. 148, no. 11, p. 3880 - 3892
|0 PERI:(DE-600)1474117-9
|n 11
|p 3880 - 3892
|t Brain
|v 148
|y 2025
|x 0006-8950
856 4 _ |u https://pub.dzne.de/record/281877/files/DZNE-2025-01248.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/281877/files/DZNE-2025-01248.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)2811659
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 32
|6 P:(DE-2719)2811275
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 111
|6 P:(DE-2719)9000375
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 112
|6 P:(DE-2719)9001369
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 123
|6 P:(DE-2719)9001508
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 125
|6 P:(DE-2719)9001249
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 127
|6 P:(DE-2719)9002620
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 128
|6 P:(DE-2719)9002610
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-12
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRAIN : 2022
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-12
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-12
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b BRAIN : 2022
|d 2024-12-12
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 1
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21